In my opinion, its a fairly good Ann. Focusing on what they do best and selling out what they bought at a higher price to retire debt is reasonable(compared to a CR which most other company would have typically done). SE1 would also have used the tech knowledge from Nanotron to improved their core services these few years. 41% increase in revenue, lower cost of business and with the rise of biomedical and biotech industry, i believe this is a good move.
